P
PIN Pharma
Providing online marketing services
About PIN Pharma
PIN Pharma is a biopharmaceutical company dedicated to developing broad-based immunomodulatory therapies. The company employs a unique approach to connect the innate and adaptive immune systems, aiming to combat immunosuppression, cancer, and autoimmune diseases. PIN Pharma's primary focus is on oncology, but its technology has potential applications across various other disease areas. The company utilizes precision immune stimulants (PINs) derived from Transactivator of Transcription (Tat) proteins, known for their high potency and efficacy at low doses.
PIN Pharma operates in the biopharmaceutical market, targeting healthcare providers, research institutions, and pharmaceutical companies. Its business model revolves around research and development, with revenue generated through venture backing, licensing agreements, and potential future sales of its therapeutic products.
Source: Dealroom company dataAt a glance
- Founded
- 2011
- Headquarters
- New York City, United States
- Sector
- Health
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
NGN Capital
Partnership Fund for New York City
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about PIN Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PIN Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.